BELLUS Health Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Montreal--(business wire)--bellus health inc. (nasdaq: blu; tsx: blu.to) (“bellus” or the “company”) today announced the positive outcome of the bellus shareholders (“shareholders”) vote at this morning's special meeting of the shareholders (the “special meeting”) held in-person, approving the previously-announced statutory plan of arrangement under section 192 of the canada business corporations act (the “arrangement”) pursuant to which 14934792 canada inc. (the “purchaser”), a corporation exi.

Plantation, fla.--(business wire)--alliance entertainment holding corporation (otc: aent) (“alliance entertainment”, “company”), a distributor and wholesaler of the world’s largest in stock selection of music, movies, video games, electronics, arcades, and collectibles, has reported its financial and operational results for the fiscal third quarter and nine-month period ended march 31, 2023. third quarter and subsequent 2023 operational highlights completed its business combination with adara acquisition corp. 2023 record store day on saturday, april 22, 2023 broke a sales record for most vinyl sold in a single day with more than 800,000 units of vinyl created and shipped to participating independent record stores and retail sales expected to surpass $32 million...

MontrÉal--(business wire)--bellus santÉ inc. (nasdaq : blu; tsx : blu.to) (« bellus » ou la « sociÉtÉ ») a annoncÉ aujourd’hui que la cour supÉrieure du quÉbec a rendu une ordonnance provisoire autorisant, entre autres choses, la tenue d’une assemblÉe extraordinaire (l’« assemblÉe extraordinaire ») des actionnaires de bellus (les « actionnaires ») le 16 juin 2023. À l’assemblÉe extraordinaire, il sera demandÉ aux actionnaires d’examiner et, s’ils le jugent souhaitable, d’adopter une rÉsolution extraordinaire (la « rÉsolution relative À l’arrangement ») qui approuve le plan d’arrangement aux termes de l’article 192 de la loi canadienne sur les sociÉtÉs par actions qui a ÉtÉ annoncÉ prÉcÉdemment (l’« arrangement ») dans le cadre duquel 14934792 canada inc...

Montreal--(business wire)--bellus health inc. (nasdaq: blu; tsx: blu.to) (“bellus” or the “company”) today announced that the superior court of quÉbec has issued an interim order authorizing, among other things, the holding of a special meeting (the “special meeting”) of shareholders of bellus (“shareholders”) on june 16, 2023. at the special meeting, shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the “arrangement resolution”) approving the previ.

Laval, quebec--(business wire)--bellus health inc. (nasdaq:blu; tsx:blu) (“bellus health” or the “company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (blu-5937) for the treatment of refractory chronic cough (“rcc”), today reported its financial and operating results for the quarter ended march 31, 2023. “our merger agreement with gsk underscores our corporate and clinical achievements to date and marks the start of a new chapter for our potentially best-in-class p2x3 receptor antagonist, camlipixant,” commented roberto bellini, president and chief executive officer of bellus health...

BELLUS Health Inc (TSX:BLU) said its shareholders overwhelmingly have approved a US$2 billion takeover by GSK PLC (LSE:GSK, NYSE:GSK). The late-stage biopharmaceutical firm said in a statement that almost 100% of shareholders at a special meeting voted in favor of the US$14.75 per share offer.

U.K.-based GSK is buying Canadian biotech Bellus Health for $2 billion. The purchase will include a promising drug candidate for treating chronic cough.

Bellus' lead therapy, camlipixant, is being tested against refractory chronic cough. The company is a clinical-stage biotech with no marketed therapies.

Bellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news.

11:55am: Bellus Health (TSX:BLU), The Lion Electric Company shares make big gains  BELLUS Health Inc (Bellus Health (TSX:BLU)) shares shot up 99% to $19.33 on Tuesday after the late-stage biopharmaceutical company announced that it has agreed to be acquired by GSK PLC (LSE:GSK, NYSE:GSK) for US$14.75 per share in cash.   As well, shares of The Lion Electric Company (TSX:LEV) shares continued to move higher Tuesday, up 19% to $3.13 following a 12% gain on Monday, as the manufacturer of all-electric medium and heavy-duty vehicles said it officially introduced its new manufacturing factory in Mirabel, Quebec, which will produce lithium-ion batteries for medium and heavy-duty vehicles.

BELLUS Health and GSK have agreed on a $2 billion buyout agreement. Through this deal, GSK will acquire a late-stage chronic cough medication that could be worth billions in peak sales.

GSK added to a series of recent takeovers Tuesday with the $2 billion acquisition of Bellus Health. But BLU stock and GSK stock diverged.

Here are some of the biggest movers on Tuesday:

GSK PLC (LSE:GSK, NYSE:GSK) has paid around £1.6bn for Bellus Health (TSX:BLU) Inc, a Canada-based, late-stage biopharmaceutical company which specialises in respiratory treatments. The pharmaceuticals giant said the deal further strengthens specialty its medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough.

GSK PLC said Tuesday that it has reached an agreement to buy the late-stage biopharmaceutical company Bellus Health Inc. BLU, +3.08% BLU, +2.83% for $14.75 a share in cash, representing a total equity value of around $2.0 billion.